ACC 2019: What the Latest Procedural Advancements Might Mean for Medtech

Posted by Eric Sin on April 16, 2019

Just a couple of weekends ago, I sat in the crowd at the American College of Cardiology (ACC) conference in New Orleans as Dr. Leon and Dr. Reardon presented on transcatheter aortic valve replacement (TAVR) trials in low-surgical-risk aortic stenosis (AS) patients. These findings will not only raise paradigm-shifting questions for the AS market but also prompt discussion around some common industry dilemmas, especially for markets where effective but expensive procedure options become more widely accepted for broader patient populations.


>
Read More

Gut Feeling, Instinct, Anecdotal Evidence: Why Can’t We Just Use Data for Commercial Decisions?

Posted by Lukas Grabner on April 11, 2019

I’m often surprised by the amount of commercial strategy decisions that medtech leaders need to make despite a lack of analytic proof points. Many times, important conclusions are reached by an overemphasis on instinct, anecdotal evidence and individual in-market experiences but limited quantifiable backing. 


>
Read More

Putting the ‘Strategy’ Into Strategic Account Management

Posted by Bret Caldwell on March 26, 2019

Almost every medtech company has some form of a strategic account management (SAM) program and no one is happy with it. OK, perhaps that’s an oversimplification, but I can count on one hand the number of people I’ve met who thought they had a well-functioning and profitable program to strategically cover key accounts. 


>
Read More

Value-Based Healthcare Is So 2015. Now Products Are the Talk of Medtech

Posted by Brian Chapman on March 20, 2019

For as long as I can remember, value-based healthcare has been the talk of the medtech industry, and for good reason: Who can argue with efforts to improve patient outcomes at a lower cost? With such virtuous and unassailable aims, it’s the irresistible force that dominated strategies in the last decade.


>
Read More

Into 2019: Risk, Uncertainty and a Return to Product Focus

Posted by Brian Chapman on January 23, 2019

Looking ahead to what the medtech industry can expect in 2019, I see a continuation of some of the greatest accomplishments of 2018, such as ongoing collaboration with regulatory bodies and real-world evidence driving more reimbursement discussions, as well as the brave new world of digital health continuing to buoy how our industry can help patients.


>
Read More